P123 | IBRUTINIB AND VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS OUTSIDE CLINICAL TRIALS: A SINGLE-CENTER REAL-WORLD EXPERIENCE
Introduction: The combination of ibrutinib, a Bruton's tyrosine kinase inhibitor, and venetoclax, a BCL-2 inhibitor, has shown synergistic efficacy in chronic lymphocytic leukemia (CLL). Pivotal trials like CAPTIVATE and GLOW report high rates of complete remission (CR) and undetectable minimal res...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Ferrata Storti Foundation
2025-09-01
|
| Seri Bilgileri: | Haematologica |
| Online Erişim: | https://haematologica.org/article/view/12420 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|